

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Subjective disease severity and disease acceptance scale among respondents

Category	Group	Number of respondents	Percentage (%)
Subjective severity	mild	100	30.0%
	moderate	175	52.6%
	severe	58	17.4%
AIS	poor	55	16.5%
	moderate	104	31.2%
	good	174	52.3%

AIS: the Acceptance of Illness Scale.

Table SII. Prevalence and characteristics of body modifications among respondents

Category	Variable	Value
Tattoo characteristics	Mean number of tattoos	4.0 ± 4.1
	Mean body surface area covered (%)	7.9 ± 6.4
Tattoo locations	Forearms	32 (25.2%)
	Thighs	18 (14.2%)
	Arms	14 (11.0%)
	Lower legs	13 (10.2%)
	Palms	12 (9.4%)
	Abdomen	11 (8.7%)
	Chest	10 (7.9%)
	Foot	9 (7.1%)
	Head	6 (4.7%)
	Intimate areas	2 (1.6%)
Piercing characteristics	Mean number of piercings	3.7 ± 2.4
Piercing locations	Ears	45 (63.4%)
	Nose	11 (15.5%)
	Navel	10 (14.1%)
	Tongue	3 (4.2%)
	Nipples	2 (2.8%)

Table SIII. The characteristics of patients with and without body modification in specific chronic dermatoses. Differences between groups were determined using a two-sample *t*-test and post-hoc chi-square test with Bonferroni's adjustment

	With body modification (n=98)	Without body modification (n=235)	p-value
Psoriasis	31 (31.6%)	72 (30.6%)	N/A
Atopic dermatitis	13 (13.3%)	35 (14.9%)	N/A
Eczema	10 (10.2%)	29 (12.3%)	N/A
Acne	11 (11.2%)	9 (3.8%)	N/A
Alopecia areata	4 (4.1%)	9 (3.8%)	p<0.05
Hidradenitis suppurativa	7 (7.1%)	5 (2.1%)	p<0.05
Scarring alopecia	2 (2%)	8 (3.4%)	N/A
Rosacea	2 (2%)	6 (2.6%)	N/A
Prurigo nodularis	2 (2%)	4 (1.7%)	N/A
Bullous diseases	0 (0%)	7 (3%)	p<0.05
Urticaria	4 (4.1%)	2 (0.9%)	N/A
Mycosis fungoides	0 (0%)	6 (2.6%)	p<0.05
Connective tissue diseases	0 (0%)	6 (2.6%)	p<0.05
Lichen planus	1 (1%)	4 (1.7%)	N/A
Morphea	1 (1%)	4 (1.7%)	N/A
Androgenic alopecia	2 (2%)	3 (1.3%)	N/A
Vitiligo	1 (1%)	3 (1.3%)	N/A
Granuloma annulare	1 (1%)	5 (2.1%)	N/A
Seborrheic dermatitis	2 (2%)	4 (1.7%)	N/A
Lichen sclerosus	0 (0%)	4 (1.7%)	p<0.05
Others	4 (4%)	10 (4.3%)	N/A

Abbreviation 1: N/A—not applicable.

N/A indicates that a p-value could not be calculated because statistical testing was not applicable (e.g., expected cell counts were too small or the distribution across groups did not meet the assumptions of the chi-square test).

Table SIV. The characteristics of patients with poor, moderate or good acceptance of specific chronic dermatologic disease. Differences between groups were determined using a single factor ANOVA test and post-hoc chi-square test with Bonferroni's adjustment

	Poor acceptance of the dermatologic disease (n=55)	Moderate acceptance of the dermatologic disease (n=104)	Good acceptance of the dermatologic disease (n=174)	p-value
Psoriasis	18 (32.7%)	34 (32.7%)	51 (29.3%)	N/A
Atopic dermatitis	9 (16.4%)	20 (19.2%)	19 (10.9%)	N/A
Eczema	6 (10.9%)	9 (8.7%)	24 (13.8%)	N/A
Acne	1 (1.8%)	3 (2.9%)	16 (9.2%)	p<0.05
Alopecia areata	2 (3.6%)	4 (3.8%)	7 (4%)	N/A
Hidradenitis suppurativa	4 (7.3%)	3 (2.9%)	5 (2.9%)	N/A
Scarring alopecia	1 (1.8%)	1 (1%)	8 (4.6%)	N/A
Rosacea	0 (0%)	6 (5.8%)	2 (1.1%)	p<0.05
Prurigo nodularis	3 (5.5%)	1 (1%)	2 (1.1%)	N/A
Bullous diseases	1 (1.8%)	3 (2.9%)	3 (1.7%)	N/A
Urticaria	0 (0%)	2 (1.9%)	4 (2.3%)	N/A
Mycosis fungoides	1 (1.8%)	0 (0%)	5 (2.9%)	N/A
Connective tissue diseases	3 (5.5%)	3 (2.9%)	0 (0%)	p<0.05
Lichen planus	1 (1.8%)	2 (1.9%)	2 (1.1%)	N/A
Morphea	0 (0%)	3 (2.9%)	2 (1.1%)	N/A
Androgenic alopecia	0 (0%)	1 (1%)	4 (2.3%)	N/A
Vitiligo	0 (0%)	1 (1%)	3 (1.7%)	N/A
Granuloma annulare	0 (0%)	4 (3.8%)	2 (1.1%)	N/A
Seborrheic dermatitis	1 (1.8%)	1 (1%)	4 (2.3%)	N/A
Lichen sclerosus	2 (3.6%)	0 (0%)	2 (1.1%)	N/A
Others	2 (3.6%)	3 (2.9%)	9 (5.2%)	N/A

Abbreviation 1: N/A—not applicable.

N/A indicates that a p-value could not be calculated because statistical testing was not applicable (e.g., expected cell counts were too small or the distribution across groups did not meet the assumptions of the chi-square test).

Table SV. The characteristics of patients screened positive with body dysmorphic tendencies compared to patients without these symptoms in specific chronic dermatoses. Differences between groups were determined using a two-sample *t*-test and post-hoc chi-square test with Bonferroni's adjustment

	BDD tendencies (n=53)	non-BDD tendencies (n=280)	p-value
Psoriasis	17 (32.1%)	86 (30.7%)	N/A
Atopic dermatitis	9 (17%)	39 (13.9%)	N/A
Eczema	5 (9.4%)	34 (12.1%)	N/A
Acne	7 (13.2%)	13 (4.6%)	N/A
Alopecia areata	3 (5.7%)	10 (3.6%)	N/A
Hidradenitis suppurativa	3 (5.7%)	9 (3.2%)	N/A
Scarring alopecia	1 (1.9%)	9 (3.2%)	N/A
Rosacea	1 (1.9%)	7 (2.5%)	N/A
Prurigo nodularis	1 (1.9%)	5 (1.8%)	N/A
Bullous diseases	0 (0%)	7 (2.5%)	p<0.05
Urticaria	0 (0%)	6 (2.1%)	p<0.05
Mycosis fungoides	0 (0%)	6 (2.1%)	p<0.05
Connective tissue diseases	0 (0%)	6 (2.1%)	p<0.05
Lichen planus	1 (1.9%)	4 (1.4%)	N/A
Morphea	0 (0%)	5 (1.8%)	p<0.05
Androgenic alopecia	1 (1.9%)	4 (1.4%)	N/A
Vitiligo	1 (1.9%)	3 (1.1%)	N/A
Granuloma annulare	1 (1.9%)	5 (1.8%)	N/A
Seborrheic dermatitis	1 (1.9%)	5 (1.8%)	N/A
Lichen sclerosis	0 (0%)	4 (1.4%)	p<0.05
Others	1 (1.9%)	13 (4.6%)	N/A

Abbreviation 1: BDD—Body Dysmorphic Disorder; Abbreviation 2: N/A—not applicable.

N/A indicates that a p-value could not be calculated because statistical testing was not applicable (e.g., expected cell counts were too small or the distribution across groups did not meet the assumptions of the chi-square test).